Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival.
Saved in:
| Title: | Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. |
|---|---|
| Authors: | Roca-Pereira S; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain., López-Sampere Y; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain., Mengod-Soler P; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain., Peña-Fonteboa M; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Marco C; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Caravaca-Puchades A; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Domínguez R; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Vázquez-Costa JF; Neuromuscular Unit and ERN-NMD Group, Department of Neurology, Hospital Universitario y Politécnico La Fe and IIS La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Medicine, Universitat de València, Valencia, Spain., Santamaría E; Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Fernández-Irigoyen J; Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Colomina MJ; Anesthesia and Critical Care Department, Bellvitge University Hospital-University of Barcelona L'Hospitalet de Llobregat, Barcelona, Spain., León Moreno I; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Martínez Yélamos A; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain., Martínez Yélamos S; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain., Santpere G; Neurogenomics Group, Hospital del Mar Research Institute, Parc de Recerca Biomèdica de Barcelona (PRBB), Barcelona, Catalonia, Spain., Obis E; Metabolic Pathophysiology Research Group, Department of Experimental Medicine, University of Lleida-IRB, Lleida, Spain., Portero-Otín M; Metabolic Pathophysiology Research Group, Department of Experimental Medicine, University of Lleida-IRB, Lleida, Spain., Piñol-Ripoll G; Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain.; Unitat de Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, Lleida, Spain.; Department of Experimental Medicine, Faculty of Medicine, Universitat de Lleida (UdL), Lleida, Spain., Povedano M; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Andrés-Benito P; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain. |
| Source: | Brain pathology (Zurich, Switzerland) [Brain Pathol] 2026 Mar 03, pp. e70089. Date of Electronic Publication: 2026 Mar 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: International Society of Neuropathology Country of Publication: Switzerland NLM ID: 9216781 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-3639 (Electronic) Linking ISSN: 10156305 NLM ISO Abbreviation: Brain Pathol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41776751 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Roca-Pereira+S%22">Roca-Pereira S</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22López-Sampere+Y%22">López-Sampere Y</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Mengod-Soler+P%22">Mengod-Soler P</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Peña-Fonteboa+M%22">Peña-Fonteboa M</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Marco+C%22">Marco C</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Caravaca-Puchades+A%22">Caravaca-Puchades A</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Domínguez+R%22">Domínguez R</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vázquez-Costa+JF%22">Vázquez-Costa JF</searchLink>; Neuromuscular Unit and ERN-NMD Group, Department of Neurology, Hospital Universitario y Politécnico La Fe and IIS La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Medicine, Universitat de València, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Santamaría+E%22">Santamaría E</searchLink>; Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Fernández-Irigoyen+J%22">Fernández-Irigoyen J</searchLink>; Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Colomina+MJ%22">Colomina MJ</searchLink>; Anesthesia and Critical Care Department, Bellvitge University Hospital-University of Barcelona L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22León+Moreno+I%22">León Moreno I</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez+Yélamos+A%22">Martínez Yélamos A</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez+Yélamos+S%22">Martínez Yélamos S</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Santpere+G%22">Santpere G</searchLink>; Neurogenomics Group, Hospital del Mar Research Institute, Parc de Recerca Biomèdica de Barcelona (PRBB), Barcelona, Catalonia, Spain.<br /><searchLink fieldCode="AU" term="%22Obis+E%22">Obis E</searchLink>; Metabolic Pathophysiology Research Group, Department of Experimental Medicine, University of Lleida-IRB, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Portero-Otín+M%22">Portero-Otín M</searchLink>; Metabolic Pathophysiology Research Group, Department of Experimental Medicine, University of Lleida-IRB, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Piñol-Ripoll+G%22">Piñol-Ripoll G</searchLink>; Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain.; Unitat de Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, Lleida, Spain.; Department of Experimental Medicine, Faculty of Medicine, Universitat de Lleida (UdL), Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Povedano+M%22">Povedano M</searchLink>; Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Andrés-Benito+P%22">Andrés-Benito P</searchLink>; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.; Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229216781%22">Brain pathology (Zurich, Switzerland)</searchLink> [Brain Pathol] 2026 Mar 03, pp. e70089. <i>Date of Electronic Publication: </i>2026 Mar 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22International+Society+of+Neuropathology%22">International Society of Neuropathology </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>9216781 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1750-3639 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210156305%22">10156305 </searchLink><i>NLM ISO Abbreviation: </i>Brain Pathol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41776751 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/bpa.70089 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e70089 Titles: – TitleFull: Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Roca-Pereira S – PersonEntity: Name: NameFull: López-Sampere Y – PersonEntity: Name: NameFull: Mengod-Soler P – PersonEntity: Name: NameFull: Peña-Fonteboa M – PersonEntity: Name: NameFull: Marco C – PersonEntity: Name: NameFull: Caravaca-Puchades A – PersonEntity: Name: NameFull: Domínguez R – PersonEntity: Name: NameFull: Vázquez-Costa JF – PersonEntity: Name: NameFull: Santamaría E – PersonEntity: Name: NameFull: Fernández-Irigoyen J – PersonEntity: Name: NameFull: Colomina MJ – PersonEntity: Name: NameFull: León Moreno I – PersonEntity: Name: NameFull: Martínez Yélamos A – PersonEntity: Name: NameFull: Martínez Yélamos S – PersonEntity: Name: NameFull: Santpere G – PersonEntity: Name: NameFull: Obis E – PersonEntity: Name: NameFull: Portero-Otín M – PersonEntity: Name: NameFull: Piñol-Ripoll G – PersonEntity: Name: NameFull: Povedano M – PersonEntity: Name: NameFull: Andrés-Benito P IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 03 Text: 2026 Mar 03 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1750-3639 Titles: – TitleFull: Brain pathology (Zurich, Switzerland) Type: main |
| ResultId | 1 |
